

M-Son Nasal Spray

Mometasone Furoate USP 50mcg/metered spray

Composition : Each metered spray contains Mometasone Furoate USP 50mcg.

Pharmacology : Mometasone Furoate monohydrate is a corticosteroid demonstrating anti-inflammatory properties. The precise mechanism of corticosteroid action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (eg, mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (eg, histamines, eicosanoids, leukotrienes, and cytokines) involved in inflammation. Protein binding for Mometasone Furoate was reported to be 98% to 99% in concentration range of 5 to 500 mg/ml. The effective plasma elimination half life of Mometasone Furoate is 5.8 hours.

Indication : This nasal spray is indicated for the treatment of the nasal symptoms of seasonal & perennial allergic rhinitis in adults and pediatric patients 2 years of age and older. It is indicated for the prophylaxis of the nasal symptoms of seasonal allergic rhinitis in adult and adolescent patients 12 years of age and older. It is also indicated for the treatment of nasal polyps in patients 18 years of age and older.

Dosage and Administration : Allergic rhinitis: Adults & children 12 years of age and older: The recommended dose for prophylaxis & treatment of the nasal symptoms of seasonal allergic rhinitis and treatment of the nasal symptoms of perennial allergic rhinitis is 2 sprays in each nostril once daily. In patients with a known seasonal allergen that precipitates nasal symptoms of seasonal allergic rhinitis, prophylaxis with this nasal spray, 50mcg (200 mcg/day) is recommended 2 to 4 weeks prior to the anticipated start of the pollen season. **Children 2 to 11 years of age :** The recommended dose for treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis is 1 spray (50mcg of mometasone furoate in each spray) in each nostril once daily (total daily dose of 100 mcg). **Nasal polyps : Adults 18 years of age & older:** The recommended dose for the treatment of nasal polyps is 2 sprays (50 mcg of mometasone furoate in each spray) in each nostril twice daily (total daily dose of 400 mcg). A dose of 2 sprays (50 mcg of mometasone furoate in each spray) in each nostril once daily (total daily dose of 200 mcg) is also effective in some patients. Or, as directed by the registered physician.

Contraindication : It is contraindicated in patients with known hypersensitivity to mometasone furoate or any other ingredients of this preparation.

Precautions : While using nasal corticosteroids, caution is required in patients with active or dormant tuberculous infection or in untreated fungal, bacterial, systemic viral infections or ocular herpes simplex.

Side effects : Side effects are generally mild & included headache, viral infection, sore throat, nosebleeds and coughing.

Pregnancy and Lactation : Pregnancy category C. There are no adequate & well controlled studies in pregnant woman. Mometasone Furoate, like other corticosteroids, should be used during pregnancy only if the potential benefits justify the potential risk to the fetus. It is not known if Mometasone Furoate is excreted in human milk. Because other corticosteroids are excreted in human milk, caution should be used when Mometasone Furoate is administered to nursing women.

Use in child : See dosage and administration.

Drug Interactions : No information provided.

Overdose : There are no data available on the effects of acute or chronic overdosage with mometasone furoate. Because of low systemic bioavailability and an absence of acute drug-related systemic findings in clinical studies, overdose is unlikely to require any therapy other than observation.

Storage : Store below 30°C, protect from light.

Packing : Each bottle contains 120 metered doses for sprays.

Manufactured by
 **DRUG INTERNATIONAL LTD.**
Tongi, Gazipur, Bangladesh